Contrast-Enhanced Spectral Mammography-Based Radiomics Nomogram for the Prediction of Neoadjuvant Chemotherapy-Insensitive Breast Cancers

• Published in: Frontiers in oncology Vol. 11; p. 605230
• Main Authors: Wang, Zhongyi, Lin, Fan, Ma, Heng, Shi, Yinghong, Dong, Jianjun, Yang, Ping, Zhang, Kun, Guo, Na, Zhang, Ran, Cui, Jingjing, Duan, Shaofeng, Mao, Ning, Xie, Haizhu
• Format: Journal Article
• Language: English
• Published: Switzerland Frontiers Media S.A 22-02-2021
• Subjects: breast cancer; contrast-enhanced spectral mammograph; neoadjuvant chemotherapy; Oncology; radiomics; neoadjuvant chemotherapy; radiomics; breast cancer; contrast-enhanced spectral mammograph; oncology
• ISSN: 2234-943X; 2234-943X
• DOI: 10.3389/fonc.2021.605230

We developed and validated a contrast-enhanced spectral mammography (CESM)-based radiomics nomogram to predict neoadjuvant chemotherapy (NAC)-insensitive breast cancers prior to treatment.
We enrolled 117 patients with breast cancer who underwent CESM examination and NAC treatment from July 2017 to April 2019. The patients were grouped randomly into a training set (n = 97) and a validation set (n = 20) in a ratio of 8:2. 792 radiomics features were extracted from CESM images including low-energy and recombined images for each patient. Optimal radiomics features were selected by using analysis of variance (ANOVA) and least absolute shrinkage and selection operator (LASSO) regression with 10-fold cross-validation, to develop a radiomics score in the training set. A radiomics nomogram incorporating the radiomics score and independent clinical risk factors was then developed using multivariate logistic regression analysis. With regard to discrimination and clinical usefulness, radiomics nomogram was evaluated using the area under the receiver operator characteristic (ROC) curve (AUC) and decision curve analysis (DCA).
The radiomics nomogram that incorporates 11 radiomics features and 3 independent clinical risk factors, including Ki-67 index, background parenchymal enhancement (BPE) and human epidermal growth factor receptor-2 (HER-2) status, showed an encouraging discrimination power with AUCs of 0.877 [95% confidence interval (CI) 0.816 to 0.924] and 0.81 (95% CI 0.575 to 0.948) in the training and validation sets, respectively. DCA revealed the increased clinical usefulness of this nomogram.
The proposed radiomics nomogram that integrates CESM-derived radiomics features and clinical parameters showed potential feasibility for predicting NAC-insensitive breast cancers.